What Makes an Emerging Pharma Leader

Article

Editorial Director William Looney discusses the five essential characteristics exhibited by the more than 200 men and women selected by Pharmaceutical Executive as Emerging Pharma Leaders


Read all the Emerging Pharma Leader Profiles

Recent Videos
Fred Aslan
Dr. Dina Radenkovic, CEO, Gameto
Recent Regulatory Impacts on the Pain-Management Space
Fred Aslan
Fred Aslan
Fred Aslan
Related Content
Mark Frohlich: A ‘Natural’ Leader

Mark Frohlich: A ‘Natural’ Leader

Mike Hollan
March 13th 2025
Article

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

Elaina Shekhter, EPAM Chief Marketing & Strategy Officer.

Preparing for the C-Suite

Michael Wong
March 13th 2025
Article

A Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
February 10th 2025
Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Pharma Pulse 3/13/25: Notable SCOPE 2025 Discussions, Pharmacists Play Unique Role in Clean Sports & more

Pharma Pulse 3/13/25: Notable SCOPE 2025 Discussions, Pharmacists Play Unique Role in Clean Sports & more

Miranda Schmalfuhs
March 13th 2025
Article

The latest news for pharma industry insiders.

Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer

Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer

Don Tracy, Associate Editor
March 13th 2025
Article

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+/HER2- advanced or metastatic breast cancer.